Cargando…
1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico
BACKGROUND: Cancer patients (CPs) with COVID-19 have an increased risk of adverse outcomes. In addition, CPs seem to have a lower immune response to SARS-CoV-2 vaccination. This study aimed to evaluate SARS-CoV-2 spike antibodies (anti-S Abs) following COVID-19 vaccination in CPs and healthcare work...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752446/ http://dx.doi.org/10.1093/ofid/ofac492.1594 |
_version_ | 1784850724699504640 |
---|---|
author | Villaseñor-Echavarri, Rodrigo De-la-Rosa-Martinez, Daniel Frias-Jimenez, Emmanuel Martin-Onraet, Alexandra Ruiz-Garcia, Erika Cruz-Cruz, Alonso Herrera-Montalvo, Luis Alonso Vilar-Compte, Diana |
author_facet | Villaseñor-Echavarri, Rodrigo De-la-Rosa-Martinez, Daniel Frias-Jimenez, Emmanuel Martin-Onraet, Alexandra Ruiz-Garcia, Erika Cruz-Cruz, Alonso Herrera-Montalvo, Luis Alonso Vilar-Compte, Diana |
author_sort | Villaseñor-Echavarri, Rodrigo |
collection | PubMed |
description | BACKGROUND: Cancer patients (CPs) with COVID-19 have an increased risk of adverse outcomes. In addition, CPs seem to have a lower immune response to SARS-CoV-2 vaccination. This study aimed to evaluate SARS-CoV-2 spike antibodies (anti-S Abs) following COVID-19 vaccination in CPs and healthcare workers (HCWs). METHODS: We conducted a point-seroprevalence study in CPs and HCWs who received a two-dose scheme with either BNT162b2, AZD1222, or Sputnik-V vaccine. We measured anti-S Abs by quantitative immunoassay to assess humoral immune response. Besides, we quantified anti-nucleocapsid antibodies in a subgroup of individuals to determine prior infection. We compared anti-S Abs titers in both groups and stratified by vaccine type, prior infection, and clinical characteristics. We conducted a multivariate logistic regression to determine variables associated with a poor humoral response. RESULTS: Six hundred forty-one individuals were included: 174 (27%) CPs and 467 (73%) HCWs. The median anti-S Abs titter was higher among HCWs compared to CPs (2568 U/mL vs. 1807 U/mL, p=0.002). Both CPs and HCWs with prior infection had higher anti-S Abs titter (p< 0.001). Regardless of the time since vaccination, a higher proportion of subjects with titers < 250 U/mL was observed in CPs (p< 0.001) (Fig 2). In the multivariate analysis, older age (p=0.036), AZD1222 (p=0.003), and Sputnik-V (p=0.020) were associated with lower humoral response among the entire cohort. SARS-CoV-2 spike antibody titers among cancer patients and healthcare workers. [Figure: see text] Global differences in anti-S Abs titers between CPs and HCWs groups (a) and antibody titers in CPs and HCWs groups stratified by type of received vaccine (b). Abbreviations: CP: Cancer patients, HCW: Healthcare workers. SARS-CoV-2 spike antibody titers according to time since vaccination among cancer patients and healthcare workers. [Figure: see text] Abbreviations: CP: Cancer patients, HCW: Healthcare workers. CONCLUSION: In this study, both CPs and HCWs showed an adequate response to vaccination; however, CPs had lower anti-S Abs titers and a faster decline over time. Based on our results, new strategies should be assessed to sustain the humoral response to vaccination and thus decrease the COVID-19 burden among the oncologic population. DISCLOSURES: All Authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-9752446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97524462022-12-16 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico Villaseñor-Echavarri, Rodrigo De-la-Rosa-Martinez, Daniel Frias-Jimenez, Emmanuel Martin-Onraet, Alexandra Ruiz-Garcia, Erika Cruz-Cruz, Alonso Herrera-Montalvo, Luis Alonso Vilar-Compte, Diana Open Forum Infect Dis Abstracts BACKGROUND: Cancer patients (CPs) with COVID-19 have an increased risk of adverse outcomes. In addition, CPs seem to have a lower immune response to SARS-CoV-2 vaccination. This study aimed to evaluate SARS-CoV-2 spike antibodies (anti-S Abs) following COVID-19 vaccination in CPs and healthcare workers (HCWs). METHODS: We conducted a point-seroprevalence study in CPs and HCWs who received a two-dose scheme with either BNT162b2, AZD1222, or Sputnik-V vaccine. We measured anti-S Abs by quantitative immunoassay to assess humoral immune response. Besides, we quantified anti-nucleocapsid antibodies in a subgroup of individuals to determine prior infection. We compared anti-S Abs titers in both groups and stratified by vaccine type, prior infection, and clinical characteristics. We conducted a multivariate logistic regression to determine variables associated with a poor humoral response. RESULTS: Six hundred forty-one individuals were included: 174 (27%) CPs and 467 (73%) HCWs. The median anti-S Abs titter was higher among HCWs compared to CPs (2568 U/mL vs. 1807 U/mL, p=0.002). Both CPs and HCWs with prior infection had higher anti-S Abs titter (p< 0.001). Regardless of the time since vaccination, a higher proportion of subjects with titers < 250 U/mL was observed in CPs (p< 0.001) (Fig 2). In the multivariate analysis, older age (p=0.036), AZD1222 (p=0.003), and Sputnik-V (p=0.020) were associated with lower humoral response among the entire cohort. SARS-CoV-2 spike antibody titers among cancer patients and healthcare workers. [Figure: see text] Global differences in anti-S Abs titers between CPs and HCWs groups (a) and antibody titers in CPs and HCWs groups stratified by type of received vaccine (b). Abbreviations: CP: Cancer patients, HCW: Healthcare workers. SARS-CoV-2 spike antibody titers according to time since vaccination among cancer patients and healthcare workers. [Figure: see text] Abbreviations: CP: Cancer patients, HCW: Healthcare workers. CONCLUSION: In this study, both CPs and HCWs showed an adequate response to vaccination; however, CPs had lower anti-S Abs titers and a faster decline over time. Based on our results, new strategies should be assessed to sustain the humoral response to vaccination and thus decrease the COVID-19 burden among the oncologic population. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752446/ http://dx.doi.org/10.1093/ofid/ofac492.1594 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Villaseñor-Echavarri, Rodrigo De-la-Rosa-Martinez, Daniel Frias-Jimenez, Emmanuel Martin-Onraet, Alexandra Ruiz-Garcia, Erika Cruz-Cruz, Alonso Herrera-Montalvo, Luis Alonso Vilar-Compte, Diana 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico |
title | 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico |
title_full | 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico |
title_fullStr | 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico |
title_full_unstemmed | 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico |
title_short | 1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico |
title_sort | 1969. sars-cov-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of covid-19 vaccination in mexico |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752446/ http://dx.doi.org/10.1093/ofid/ofac492.1594 |
work_keys_str_mv | AT villasenorechavarrirodrigo 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT delarosamartinezdaniel 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT friasjimenezemmanuel 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT martinonraetalexandra 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT ruizgarciaerika 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT cruzcruzalonso 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT herreramontalvoluisalonso 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico AT vilarcomptediana 1969sarscov2seroprevalenceamongpatientswithcancerandhealthcareworkersfromanoncologyreferralcenterduringthefirstyearofcovid19vaccinationinmexico |